Genmab A/S (NASDAQ: GMAB) announced results from its Phase 2 EPCORE NHL-6 trial showing that 92% of patients with relapsed/refractory ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE